Loading...
Market
Story
FDA Approves Sanofi and Regeneron's Dupixent as First Biologic for COPD
Sep 27, 2024, 01:39 PM
The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab), developed by Sanofi ($SNY) and Regeneron ($REGN), as the first-ever biologic medicine for patients with Chronic Obstructive Pulmonary Disease (COPD). This approval marks a significant milestone for the drug, which has already been approved for similar use in China and by European regulators. The approval, announced on Friday, is expected to open a new chapter for Sanofi and Regeneron's blockbuster drug, commonly known as 'smoker's lung' treatment.
View original story
Similar markets
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
No new competitors • 33%
1 new competitor • 33%
2 or more new competitors • 34%
None • 25%
1 to 2 • 25%
3 to 4 • 25%
More than 4 • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0-5 • 25%
6-10 • 25%
11-15 • 25%
16 or more • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
0-1 new treatments • 25%
2-3 new treatments • 25%
4-5 new treatments • 25%
More than 5 new treatments • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
No new competitors • 25%
1 new competitor • 25%
2 new competitors • 25%
3 or more new competitors • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%